Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Sarcoma, Synovial 1Sarcoma, Myeloid 1Sarcoma 1Rhabdoid Tumor 1Neurofibrosarcoma 1Myeloproliferative Disorders 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hemangiosarcoma 1Ganglioneuroblastoma 1Fibrosarcoma 1Dermatofibrosarcoma 1Central Nervous System Neoplasms 1Blast Crisis 1

Interventions

sargramostim 3dinutuximab 3Colony-Stimulating Factors 3Temozolomide 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Isotretinoin 2Irinotecan 2temsirolimus 1Vincristine 1Topotecan 1Thiotepa 1Stem Cell Transplantation 1Sirolimus 1Razoxane 1Radiation 1Platinum 1Melphalan 1Etoposide 1Doxorubicin 1Dexrazoxane 1Cyclophosphamide 1Congresses as Topic 1Cisplatin 1Carboplatin 1Biopsy 13-fluorobenzylguanidine 13-Iodobenzylguanidine 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ganglioneuroblastoma × Razoxane × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡